ADXN ADXN
Company Profile ↓Company Overview
ADXN (ADXN) is a publicly traded company listed on with a market capitalization of $1.24B. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Recent Developments
- Dec 2025 Revenue of $29.97K (-92.6% YoY); net profit $-6.73M.
- Trailing 12 Months Year-on-year growth — revenue -92.6%, earnings -195.4%.
- 5-Year Trend Long-term compounding — revenue CAGR -72.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -72.38% |
| 1 Year: | -92.58% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -195.36% |
Stock Price Performance
| 1 Year: | -30.01% |
| 6 Months: | -25.72% |
| 3 Months: | -17.89% |
| 1 Month: | -1.73% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)46.96 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Revenue declined at -72.4% CAGR over 5 years.
- Trading 48.0% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 0 | 29.72K | 248 | 0 |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | 606.26K | 732.90K | 725.90K | 779.51K | 479.83K |
| Operating Income | - | -606.26K | -732.90K | -696.17K | -779.26K | -479.83K |
| EBITDA | - | -1.47M | -1.96M | -1.57M | -1.83M | -1.70M |
| Interest Expense | - | 548 | 829 | 472 | 575 | 956 |
| Pretax Income | - | -1.47M | -1.96M | -1.58M | -1.83M | -1.71M |
| Tax Provision | 0 | 0 | 0 | 0 | - | 0 |
| Net Income | - | -1.47M | -1.84M | -1.58M | -1.84M | -1.71M |
| Diluted EPS | - | -1.20 | -2.40 | -1.20 | - | -1.20 |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Revenue | - | 1.42M | 1.61M | 404.10K | 29.97K |
| Cost of Revenue | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Operating Expenses | - | 11.96M | 3.86M | 3.16M | 2.84M |
| Operating Income | - | -10.54M | -2.24M | -2.76M | -2.81M |
| EBITDA | - | -10.45M | -2.19M | -4.65M | -6.83M |
| Interest Expense | - | 27.95K | 3.87K | 3.55K | 2.42K |
| Pretax Income | - | -10.80M | -2.50M | -4.91M | -6.84M |
| Tax Provision | - | 0 | 0 | 0 | 0 |
| Net Income | - | -20.80M | -10.56M | 7.06M | -6.73M |
| Diluted EPS | - | -55.20 | -16.80 | 8.40 | -7.20 |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 8.28M | 4.64M | 10.68M | 6.36M |
| Current Assets | - | 7.83M | 4.23M | 3.54M | 1.68M |
| Cash & Equivalents | - | 6.96M | 3.87M | 3.34M | 1.64M |
| Inventory | - | - | - | - | - |
| Receivables | - | 416.88K | 110.36K | 15.51K | 20.09K |
| Total Liabilities | - | 3.37M | 3.50M | 1.00M | 1.60M |
| Current Liabilities | - | 3.28M | 2.89M | 802.09K | 1.20M |
| Long Term Debt | - | - | - | - | - |
| Total Debt | - | 373.13K | 344.34K | 41.99K | 34.69K |
| Total Equity | - | 4.91M | 1.15M | 9.68M | 4.77M |
| Shares Outstanding | - | 115.35M | 184.35M | 184.35M | 218.65M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | - | -16.44M | -7.99M | -5.37M | -2.17M |
| Investing Cash Flow | - | 2.97K | -6.84K | 4.65M | -680.69K |
| Financing Cash Flow | - | 3.10M | 5.26M | 104.92K | 1.18M |
| Capital Expenditure | -31.55K | -581 | -6.84K | -1.27K | - |
| Free Cash Flow | - | -16.44M | -8.00M | -5.37M | -2.17M |
| Net Change in Cash | - | -13.33M | -2.73M | -623.42K | -1.67M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | -741.0% | -139.1% | -681.8% | -9,390.8% |
| Net Margin % | - | -1,462.6% | -654.5% | 1,746.0% | -22,448.4% |
| ROE % | - | -423.5% | -921.6% | 72.9% | -141.2% |
| ROCE % | - | -210.8% | -128.3% | -27.9% | -54.5% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for ADXN
Addex Announces Publication of Research Highlighting Therapeutic Potential of mGlu7 Modulation in Regulating Sleep and Wakefulness
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, July 8, 2026 - Addex Therapeutics (SIX: ADXN and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric …
Addex Shareholders Approve All Resolutions at Annual General Meeting
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 30, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modul…
Addex Therapeutics Ltd (ADXN) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ...
Despite financial hurdles, Addex Therapeutics Ltd (ADXN) makes significant strides in drug development and strategic positioning.
Addex Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 25, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modul…
Addex Therapeutics to Report 2026 First Quarter Financial Results and Host Conference Call on June 25, 2026
Geneva, Switzerland, June 22, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modulators for neurological disorders, today ann…
Addex Convenes Annual General Meeting 2026
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 5, 2026 - Addex Therapeutics (SIX and Nasdaq: ADXN), a clinical-stage biopharmaceutical company focused on developing a portfolio of novel small molecule allosteric modula…
ADXN — Frequently Asked Questions
What is the current share price of ADXN?
As of 2026-08-05 17:25 PDT, ADXN trades at $5.69 on NASDAQ/NYSE. Its 52-week range is $5.20 to $10.95.
What is the market capitalisation of ADXN?
ADXN has a market capitalisation of $1.24B on NASDAQ/NYSE.
What is the P/E ratio of ADXN?
ADXN trades at a trailing price-to-earnings (P/E) ratio of -0.79. Its price-to-book (P/B) ratio is 261.01.
What is the return on equity (ROE) of ADXN?
ADXN has a return on equity (ROE) of -141.15%. Its return on capital employed (ROCE) is -54.49%.
Is ADXN a good stock to buy?
This page provides a data-driven analysis of ADXN, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.